Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105
Pranav Gupta(St. John's University), Mark J. Ratain(University of Chicago), Ravi Vij(Washington University in St. Louis), Robert P. Hasserjian(Massachusetts General Hospital), Kouros Owzar(Duke University), Ben L. Sanford(Duke University), Richard A. Larson(Urbana University), Daohai Yu(Fox Chase Cancer Center), A. A. Miller(Leukemia Research Foundation), D. J. Murry(Leukemia Research Foundation)
Cited by 3
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k